Literature DB >> 23188538

Low expression of PAI-2 as a novel marker of portal vein tumor thrombosis and poor prognosis in hepatocellular carcinoma.

Li Zhou1, Ye Jin, Quan-Cai Cui, Ke-Min Jin, Wei-Xun Zhou, Bao-Cai Xing.   

Abstract

BACKGROUND: Plasminogen activator inhibitor (PAI)-2 was previously shown to be less frequently expressed in hepatocellular carcinoma (HCC). The present study was designed to investigate the clinical, pathological, and prognostic significance of PAI-2 expression in HCC.
METHODS: Expression of PAI-2 was detected immunohistochemically for specimens from 78 patients with HCC after hepatic resection and correlated with clinicopathological features and patient survival. Risk factors of portal vein tumor thrombosis (PVTT) were also analyzed.
RESULTS: Positive PAI-2 staining was observed in tumor and non-tumor tissues from 21 (26.9%) and 56 (71.8%) patients, respectively. Plasminogen activator inhibitor-2 negativity in tumor tissues was significantly associated with PVTT, with a high sensitivity not only in univariate analysis but also in multivariate analysis. In addition, positive PAI-2 staining was related to smaller tumor size and prolonged patient survival. The Cox regression model identified intratumoral PAI-2 staining as an independent prognosticator in patients with HCC after resection.
CONCLUSIONS: Our data demonstrated that low expression of PAI-2 serves as a novel marker of PVTT and poor prognosis in HCC.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23188538     DOI: 10.1007/s00268-012-1866-8

Source DB:  PubMed          Journal:  World J Surg        ISSN: 0364-2313            Impact factor:   3.352


  28 in total

Review 1.  The hallmarks of cancer.

Authors:  D Hanahan; R A Weinberg
Journal:  Cell       Date:  2000-01-07       Impact factor: 41.582

2.  Primary carcinoma of the liver: a study of 100 cases among 48,900 necropsies.

Authors:  H A EDMONDSON; P E STEINER
Journal:  Cancer       Date:  1954-05       Impact factor: 6.860

3.  Predictors of microvascular invasion before hepatectomy for hepatocellular carcinoma.

Authors:  Masaki Kaibori; Morihiko Ishizaki; Kosuke Matsui; A-Hon Kwon
Journal:  J Surg Oncol       Date:  2010-10-01       Impact factor: 3.454

4.  Global cancer statistics, 2002.

Authors:  D Max Parkin; Freddie Bray; J Ferlay; Paola Pisani
Journal:  CA Cancer J Clin       Date:  2005 Mar-Apr       Impact factor: 508.702

5.  Tumor size predicts the biological behavior and influence of operative modalities in hepatocellular carcinoma.

Authors:  Say June Kim; Kyung Keun Lee; Dong Goo Kim
Journal:  Hepatogastroenterology       Date:  2010 Jan-Feb

6.  Plasminogen- and colony-stimulating factor-1-associated markers in bladder carcinoma: diagnostic value of urokinase plasminogen activator receptor and plasminogen activator inhibitor type-2 using immunocytochemical analysis.

Authors:  Pierre Champelovier; Nathalie Boucard; Geraldine Levacher; Annick Simon; Daniel Seigneurin; Vincent Praloran
Journal:  Urol Res       Date:  2002-08-15

7.  Characterisation of a novel cell line (CSQT-2) with high metastatic activity derived from portal vein tumour thrombus of hepatocellular carcinoma.

Authors:  T Wang; H S Hu; Y X Feng; J Shi; N Li; W X Guo; J Xue; D Xie; S R Liu; M C Wu; S Q Cheng
Journal:  Br J Cancer       Date:  2010-05-11       Impact factor: 7.640

8.  Inhibition of retinoblastoma protein degradation by interaction with the serpin plasminogen activator inhibitor 2 via a novel consensus motif.

Authors:  Grant A Darnell; Toni M Antalis; Ricky W Johnstone; Brett W Stringer; Steven M Ogbourne; David Harrich; Andreas Suhrbier
Journal:  Mol Cell Biol       Date:  2003-09       Impact factor: 4.272

9.  Urokinase-type plasminogen activator system in breast cancer: association with tamoxifen therapy in recurrent disease.

Authors:  Marion E Meijer-van Gelder; Maxime P Look; Harry A Peters; Manfred Schmitt; Nils Brünner; Nadia Harbeck; Jan G M Klijn; John A Foekens
Journal:  Cancer Res       Date:  2004-07-01       Impact factor: 12.701

10.  TOP2A overexpression in hepatocellular carcinoma correlates with early age onset, shorter patients survival and chemoresistance.

Authors:  Nathalie Wong; Winnie Yeo; Wai-Lap Wong; Navy L-Y Wong; Kathy Y-Y Chan; Frankie K-F Mo; Jane Koh; Stephan Lam Chan; Anthony T-C Chan; Paul B-S Lai; Arthur K-K Ching; Joanna H-M Tong; Ho-Keung Ng; Philip J Johnson; Ka-Fai To
Journal:  Int J Cancer       Date:  2009-02-01       Impact factor: 7.396

View more
  5 in total

1.  Relationships Between Indices of Tumor Aggressiveness in Hepatocellular Carcinoma.

Authors:  Brian I Carr; Vito Guerra; Rossella Donghia; Seai Yilmaz
Journal:  J Gastrointest Cancer       Date:  2021-10-06

2.  Down-regulation of SerpinB2 is associated with gefitinib resistance in non-small cell lung cancer and enhances invadopodia-like structure protrusions.

Authors:  Song Yi Bae; Hyen Joo Park; Ji-Young Hong; Hye-Jung Lee; Sang Kook Lee
Journal:  Sci Rep       Date:  2016-08-25       Impact factor: 4.379

3.  Low expression of SerpinB2 is associated with reduced survival in lung adenocarcinomas.

Authors:  Maria Ramnefjell; Christina Aamelfot; Lars Helgeland; Lars A Akslen
Journal:  Oncotarget       Date:  2017-10-03

Review 4.  New Evidence and Perspectives on the Management of Hepatocellular Carcinoma with Portal Vein Tumor Thrombus.

Authors:  Jun Yin; Wen-Tao Bo; Jian Sun; Xiao Xiang; Jin-Yi Lang; Jian-Hong Zhong; Le-Qun Li
Journal:  J Clin Transl Hepatol       Date:  2017-03-30

Review 5.  Multidisciplinary management of hepatocellular carcinoma with portal vein tumor thrombus - Eastern Hepatobiliary Surgical Hospital consensus statement.

Authors:  Shuqun Cheng; Jiamei Yang; Feng Shen; Weiping Zhou; Yi Wang; Wenming Cong; Guang Shun Yang; Hongyan Cheng; Heping Hu; Chunfang Gao; Jia Guo; Aijun Li; Yan Meng; Xiaoqing Jiang; Yefa Yang; Guojun Qian; Ming Luo; Bing Hu; Xiaobo Man; Baohua Zhang; Changqing Su; Feiguo Zhou; Nan Li; Jie Shi; Meng Wang; Yaxin Zheng; Weixing Guo; Juxian Sun; Hongyang Wang; Wan-Yee Lau; Meng-Chao Wu
Journal:  Oncotarget       Date:  2016-06-28
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.